CVRx, Inc. (CVRX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$2.83-3.41%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Maintain revenue guidance between $63M and $67M for 2026: FY26 revenue guidance $58M-$60M vs target $63M-$67M.
CVRx aims for $63-$67 million revenue in 2026. Gross margin should stay near 86%. Operating expenses are guided between $103 million and $107 million. New Medicare coverage expands market access.
The company is still losing money and faces risks from litigation. CFO departure may hurt execution. Revenue growth and profit margins could fall short.
The price is about 44% below our fair value near $10. Analysts expect 19% revenue growth. Our view agrees but sees risks from losses and costs.
Breaks if: Gross margin falls below 85% in FY26
Breaks if: Operating expenses rise above $107 million in FY26
Breaks if: Revenue falls below $63 million or above $67 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making, and while it has some positive management initiatives, the overall risk remains high.
The market seems to have priced in a low expectations gap, indicating that CVRX is viewed as cheap compared to its peers. However, the company’s fundamentals are under scrutiny due to recent earnings misses and management changes.
Management is focused on driving revenue growth and improving gross margins, with some success in U.S. market expansion. However, controlling operating expenses has shown mixed results, and the company faces a near-term risk of missing earnings expectations.
The future performance of CVRX will depend on its ability to maintain guidance and execute on its growth strategies. Additionally, broader sector performance and economic conditions, such as job reports, could significantly impact investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss negatively impacted our view. The company did not meet revenue guidance for 2026. This miss raises concerns about future performance.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, CVRX's success will hinge on its operational execution and external market conditions. Not investment advice.